Literature DB >> 22564615

High glucose increases mesangial lipid accumulation via impaired cholesterol transporters.

K H Song1, J Park, H Ha.   

Abstract

Diabetes, whether it occurs before or after transplantation, plays an important role to decrease graft function and survival. In addition renal lipid accumulation has been suggested to play a role in the development and progression of chronic renal allograft rejection. Intracellular lipid accumulation is governed by a balance between the influx and efflux of lipid. Cholesterol transporters, such as scavenger receptor (SR)-A1, CD36, and ATP binding cassette (ABC) A1 and G1 (ABCG1), coordinate to regulate cellular lipid status. Therefore, in the present study, we examined whether high glucose caused lipid accumulation in mesangial cells as a result of altered cholesterol transporters. Mouse mesangial cells were stimulated with 30 mmol/L D-glucose (high glucose); 100 μmol/L oleic acid (OA) used as a positive control. Cellular lipid accumulation was measured by Oil Red O staining. Protein and mRNA expression of cholesterol influx (SR-A1 and CD36) and efflux (ABCA1 and ABCG1) transporters were evaluated using Western blot analysis and real-time quantitative polymerase chain reaction, respectively. High glucose was shown to significantly increase lipid accumulation in mesangial cells at 24 hours as was observed for OA. SR-A1 and CD36 mRNA expression levels were 1.5-fold and 3.5-fold higher, respectively, in high glucose-stimulated than control mesangial cell, whereas ABCG1 mRNA expression decreased to 60% of controls; however, there was no decrease in ABCA1 mRNA. Altered protein expression of each transporter in mesangial cells cultured under conditions of high glucose concentrations was consistent with mRNA expression. Osmotic control using mannitol did not significantly affect any of the measured parameters in the present study. These results demonstrated that high glucose, in itself, can induce mesangial lipid accumulation; this effect may be associated with an impaired balance between the influx and efflux of cholesterol.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564615     DOI: 10.1016/j.transproceed.2012.03.018

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

Review 1.  CD36 in chronic kidney disease: novel insights and therapeutic opportunities.

Authors:  Xiaochun Yang; Daryl M Okamura; Xifeng Lu; Yaxi Chen; John Moorhead; Zac Varghese; Xiong Z Ruan
Journal:  Nat Rev Nephrol       Date:  2017-09-18       Impact factor: 28.314

2.  Cellular cholesterol transport proteins in diabetic nephropathy.

Authors:  Joseph G S Tsun; Susan Yung; Mel K M Chau; Sammy W M Shiu; Tak Mao Chan; Kathryn C B Tan
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

Review 3.  Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury.

Authors:  Yang Zhang; Kun Ling Ma; Xiong Zhong Ruan; Bi Cheng Liu
Journal:  Int J Biol Sci       Date:  2016-03-21       Impact factor: 6.580

4.  Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.

Authors:  Ya-Ru Wu; Xiao-Yun Shi; Chun-Yan Ma; Yue Zhang; Rui-Xia Xu; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2019-11-09       Impact factor: 9.951

5.  Prediction models and nomograms of 3-year risk of chronic kidney disease in China: a study from the Shanghai Suburban Adult Cohort and Biobank (2016-2020).

Authors:  Yuting Yu; Qi Zhao; Yonggen Jiang; Na Wang; Xing Liu; Yun Qiu; Junjie Zhu; Xin Tong; Shuheng Cui; Genming Zhao
Journal:  Ann Transl Med       Date:  2021-11

6.  CD36 aggravates podocyte injury by activating NLRP3 inflammasome and inhibiting autophagy in lupus nephritis.

Authors:  Fu Lv; Yingxin He; Hongde Xu; Yongchun Li; Lipei Han; Lijie Yan; Hui Lang; Yafei Zhao; Zhanzheng Zhao; Yuanyuan Qi
Journal:  Cell Death Dis       Date:  2022-08-23       Impact factor: 9.685

7.  Visit-to-Visit Glucose Variability Predicts the Development of End-Stage Renal Disease in Type 2 Diabetes: 10-Year Follow-Up of Taiwan Diabetes Study.

Authors:  Ya-Fei Yang; Tsai-Chung Li; Chia-Ing Li; Chiu-Shong Liu; Wen-Yuan Lin; Sing-Yu Yang; Jen-Huai Chiang; Chiu-Ching Huang; Fung-Chang Sung; Cheng-Chieh Lin
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

8.  Fasting Glucose Variability as a Risk Indicator for End-Stage Kidney Disease in Patients with Diabetes: A Nationwide Population-Based Study.

Authors:  Da Young Lee; Jaeyoung Kim; Sanghyun Park; So Young Park; Ji Hee Yu; Ji A Seo; Nam Hoon Kim; Hye Jin Yoo; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Kyungdo Han; Nan Hee Kim
Journal:  J Clin Med       Date:  2021-12-18       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.